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Abstract 
Introduction and objectives. Adherence to established guidelines for patients discharged from the hospital after acute 
coronary syndrome is known to be suboptimal. The aim of this study was to assess the efficacy of a program for 
physicians centered on the treatment of acute coronary syndrome. 
Patients and method. 39 hospitals participated. Intervention: a set of measures was developed by consensus for the 
creation and distribution of educational materials. Outcomes of interest: proportion of patients in whom ejection 
fraction and residual ischemia were evaluated, treatment at discharge, and health and dietary recommendations to 
patients (smoking, diet, exercise, etc.) referred to all patients in whom these measures or treatments should have been 
used (“ideal patients”). Changes were assessed with four cross-sectional surveys. 
Results. A total of 1157, 1162, 1149, and 1158 patients were included. There were no relevant differences between 
these groups in baseline characteristics. In general, there was improvement in all variables between the first and the 
last survey. The proportion of patients who were weighed and measured increased (from 33.5% to 53.4%; P<.0001), 
as did the proportion of those in whom cholesterol was measured early (42.6 to 53.7%; P=.006). The proportion in 
whom residual ischemia was not measured despite indications for this test decreased (18.2% to 10.8%; P=.013), and 
the proportion increased for appropriate treatment with statins on discharge (68.6% to 81.4%; P<.0001), advice to 
quit smoking (60.1% to 72.2%; P<.0001) and advice to exercise (58.3% to 67.4%; P=.003). 
Conclusions. The educational intervention seems to have had a positive effect on improving the appropriateness of 
procedures and treatments for patients discharged after acute coronary syndrome. 
Resumen 
Introducción y objetivos. El cumplimiento de las recomendaciones establecidas como eficaces en el momento del alta 
en los pacientes hospitalizados por un síndrome coronario agudo es subóptimo. El objetivo de este estu-dio es evaluar 
la eficacia de un programa de intervención centrado en el abordaje y tratamiento del síndrome coronario agudo. 
Pacientes y método. Participaron en el proyecto 39 hospi-tales. La intervención realizada consistió en el desarrollo 
con-sensuado de acuerdos de mínimos y la elaboración y difusión de materiales educativos. Entre las medidas de 
interés cabe destacar la proporción de pacientes en la que se evaluaron la fracción de eyección, la isquemia residual y 
los tratamientos y recomendaciones higiénico-dietéticas en el momento del alta (tabaco, dieta, ejercicio, etc.) del total 
de pacientes en los que se deben determinar según el acuerdo de mínimos («pacientes ideales»). Asimismo, se 
valoraron los cambios en 4 cortes transversales. 
Resultados. Se incluyó a 1.157, 1.162, 1.149 y 1.158 pacientes, respectivamente. No había diferencias en las 
características basales de pacientes analizados en cada corte. En general, se aprecia una mejoría entre el primer y el 
último corte en todas las variables analizadas. Mejoró especialmente la proporción de pacientes en los que se determi-
naron el peso y la talla (del 33,5 al 53,4%; p < 0,0001). También se observó una mejoría en la medición precoz del 
colesterol (del 42,6 al 53,7%; p = 0,006) y una reducción del porcentaje de pacientes en los que no se realizó un test 
de isquemia pese a estar indicado (del 18,2 al 10,8%; p = 0,013); asimismo, aumentó la propoción de pacientes con 
un tratamiento adecuado con estatinas en el momento del alta (del 68,6 al 81,4%; p < 0,0001) y el número de 
recomendaciones sobre tabaquismo (del 60,1 al 72,2%; p < 0,0001) y ejercicio (del 58,3 al 67,4%; p = 0,003). 
Conclusiones. La intervención educativa parece que tie-ne un efecto positivo en la mejora de la adecuación de los 
procedimientos realizados y en los tratamientos prescritos en el momento del alta tras un síndrome coronario agudo. 
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Introduction 
A disparity has been recognized between the recommendations found in clinical guidelines and daily 
clinical practice which is reflected in different registries regarding the management of ischemic heart 
disease. There are many examples of this both within Spain and at international levels, some being very 
recent, in patients with acute myocardial infarction (AMI) or acute coronary syndromes.1-8 Such 
differences have been found in acute management as well as in risk stratification and secondary 
prevention strategies.2,9,10 
Although knowledge concerning this disparity could theoretically lead to improvement, practice 
shows that this is not always the case, at least, not substantially.11,12 This has led to developing strategies 
aimed at improving care in patients with ischemic heart disease. These include the identification of 
quality indicators, their correct dissemination, and the development of new tools to help reach the agreed 
quality standards.  
Currently, there is interest regarding the issue of quality in the areas of general medicine and 
cardiology.13-17 Much of this interest is due to the increasing complexity of medicine and the appearance 
of new technologies for the distribution of medical information which has led to demands for continuous 
improvement on behalf of the society.18 
Similar approaches have not been followed in Spain to date, except in very local instances. Thus, the 
aim of this study was to evaluate the effectiveness of a mainly educational intervention program for 
professionals dealing with different aspects to the approach and treatment of acute coronary syndromes 
with or with-out ST segment elevation.  
Patients and method 
General Design of the Study 
The study was done in 39 Spanish hospitals during 2002 and 2003. In the participating centers, 
follow-up was carried out on the effect of a simple intervention to improve care in patients with acute 
coronary syndrome. A general overview of the project is outlined in Figure1. The hospitals in the sample 
were selected according to convenience and not randomly. The geographical distribution of the 









Fig. 2. Geographic distribution of the participating centers. 
Description of the Intervention 
1. The development, by consensus in all centers, of a set of agreed minimums (Table 1) covering all 
the basic aspects of intervention in these patients. The quality indicators to be evaluated16 (Table 2) derive 
from this agreement.  
2. Preparation of materials to facilitate adherence with the agreed minimums: posters and leaflets 
outlining the agreed minimums and the aspects that should be improved, as well as a CD containing the 
presentation of the project and the general and specific results from every center.  
3. The materials were disseminated by distributing the leaflets among all the physicians from a 
participating service and those related to it (mainly internal medicine), by putting up the posters in areas 
where patient discharge reports are made out, and via local meetings set up to discuss and promote the 
project in every center. 
  
Table 1. Minimum Agreement* 
Hospital management: with the aim of carrying out suitable risk stratification for acute coronary patients, we agree that at 
admission the following should be done as a minimum in the absence of contraindications or impossibility (such reasons will be 
stated):  
– Measurement of total cholesterol, LDL-C, and HDL-C within the first 24 h or, if this is not possible, at any time (it will be stated 
when this was done) 
– For all AMI, EF measurement (echocardiogram, ventriculography, etc) 
– For all AMI, a residual ischemia provocation test (except for patients catheterized as a first exploration and with a demonst rated 
absence of significant lesions or in whom revascularization would be done) 
– Weigh and measure the patient 
Treatment at the time of discharge:<0} patients should receive the following treatment at the time of discharge, provided there are 
no contraindications or intolerance:  
– Platelet aggregation inhibitors: all patients except for those who present an absolute contraindication 
– Beta-blockers: all patients with AMI except for those who present absolute contraindications or very low risk (in the event o f 
non-administration state whether the lack of administration is due to these agreements) 
– ACE inhibitors: all the patients with AMI and ventricular dysfunction or clinical cardiac insufficiency except for those with 
contraindications. They are also accepted as treatment for AHT (in the event of non-administration it will be stated whether the 
lack of administration is due to these agreements) 
– Statins: all the patients with previous hypercholesterolemia (treated or untreated) or LDL-C>100 mg/dL. The reason is to 
increase the mid-term probability of prescribing statins to patients at follow-up (in the event of non-administration it will be 
stated whether  the lack of administration is due to these agreements) 
– Nitrates: not indicated in patients with AMI, unless there is angina or evidence of residual ischemia (in the event of non-
administration it will be stated whether the lack of administration is due to these agreements) 
– Calcium antagonists: not indicated in patients with AMI unless there is angina or evidence of residual ischemia (in the event of 
non-administration it will be stated whether the lack of administration is due to these agreements) 
Discharge report: the following specific recommendations should be clearly specified regarding:  
– Smoking habits 
– Diet 
– Exercise 
– Administration of sublingual nitroglycerin for the control of angina episodes 
– Target levels of lipid-lowering therapy and dosage 
– Target dose of ACE inhibitors or beta-blockers when indicated 
 
 
*LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AMI, acute myocardial 
infarction; EF, ejection fraction; ACE inhibitors, angiotensin-conversion enzyme inhibitors; AHT, arterial hypertension.  
Table 2. Quality Indicators Used in the Evaluation* 
 
A. Hospital management 
1. Percentage of patients who had total cholesterol measured within the first 24 h at admission 
2. Percentage of patients who had total cholesterol measured at some time at admission 
3. Percentage of patients who had ejection fraction measured out of the total who should be measured (agreed minimums) 
4. Percentage of patients who had a residual ischemia provocation test out of the total who should be tested (agreed minimums) 
5. Percentage of patients who are weighed and measured at admission 
B. Treatment at the time of discharge 
1. Percentage of patients who were correctly prescribed beta-blockers (agreed minimums) 
2. Percentage of patients who were correctly prescribed ACE inhibitors (agreed minimums) 
3. Percentage of patients who were correctly prescribed platelet aggregation inhibitors (agreed minimums) 
4. Percentage of patients who were correctly prescribed statins (agreed minimums) 
C. Discharge report. Percentage of patients whose discharge report included specific recommendations regarding:  
1. Smoking habits 
2. Diet 
3. Physical exercise 
4. Information related to the administration of sublingual nitroglycerin 
5. Target levels of lipid-lowering therapy and dosage 
6. Target dose of ACE inhibitors or beta-blocker (when indicated) 
7. Target dose of beta-blockers (when indicated) 
 
 
*ACE inhibitors indicates angiotensin-conversion enzyme inhibitors.  
  
Evaluation of the Intervention 
Four cross-sectional surveys were carried out. In each survey, every hospital had to select 30 
consecutive patients with a diagnosis of acute coronary syndrome (unstable angina or AMI with or 
without ST segment elevation)19 discharged alive by the participating service. In the first survey, 
information collection was carried out retrospectively, corresponding to a date prior to the beginning of 
the project, to avoid the Hawthorne effect (improvement due to knowing one is observed). In the 
remaining surveys, the information was collected prospectively based on the date indicated. The data 
sources in all cases were the discharge report and the medical record. The surveys were carried out at 
different times that coincided with the various survey stages: a) the first survey was done before the 
beginning of the study; b) the second survey was done after approving the agreed minimums; and c) the 
third and fourth surveys were carried out after distributing the intervention materials; the third soon after 
distribution began and the fourth around 4 months later (Figure 1). The final sample was made up of 4626 
patients (1157, 1162, 1149, and 1158 in surveys 1 to 4, respectively).  
An external review of the quality of the data collected was not carried out. The database was reviewed 
to detect and correct typographical errors, anomalous values or inconsistencies in the data.  
The “Ideal Patient” Concept 
These are patients who, according to the agreed minimum, should receive a specific instruction or 
procedure. The percentages presented frequently refer to these patients. This datum is interpreted as the 
percentage of patients who actually receive treatment or exploration compared to the total of those who 
should receive it according to the agreed minimums.  
Statistical Analysis 
A descriptive analysis was carried out by means of the frequency distribution of qualitative variables, 
the calculation of percentages for binary variables, and the calculation of standard measurements (mean, 
standard deviation, minimum, and maximum) for continuous variables. Confidence intervals (95% CI) 
were obtained for the percentages and means. 
The Levene test for homogeneity of variance was done to compare the variability of the percentages 
by hospital between the 4 surveys and, in the event of significant differences, a linear trend analysis of 
variance over time was carried out. 
The global percentages of the 4 cross-sectional surveys were compared through a 2-factor analysis of 
variance (survey and hospital), for which the transformation recommended for binomial data was 
previously carried out (arcsin√p, where p represents each percentage).20 As in the previous case, when 
significant differences were found a linear trend analysis of the percentages was carried out at a 5% 
significance level. 
Results 
A total of 4626 patients in the 39 participating centers were included during the study period. At 
discharge, 47.6% of patients had a diagnosis of AMI with ST segment elevation, 27.8% had AMI without 
ST segment elevation, and 24.6% had unstable angina. 
Demographic and Clinical Characteristics at Admission 
The baseline characteristics of the patients analyzed in each cross-sectional survey are presented in 
Table 3. No differences were observed in the demographic and clinical characteristics of the patients 
included in each survey.  
  
Table 3. Baseline Characteristics of the Patients* 
 Characteristics of the Patients 
 Baseline Survey Survey 2 Survey 3 Survey 4 
     
No. of patients  1157 1162 1149 1158 
Males, %  74.8 72.7 74.4 75.0 
Age, years (mean±SD)  65.3±12.3 64.7±12.6 64.2±12.9 64.6±12.6 
Discharge by service: cardiology,%  87.4 85.8 86.4 86.6 
Personal background     
Coronary disease,%  37.9 35.0 33.2 32.6 
Dyslipidemia, %  42.3 45.7 42.0 43.3 
AHT, %  52.9 54.8 54.1 54.1 
Diabetes, %  31.8 28.5 27.9 29.7 
Smoking habit, %  45.3 45.5 49.3 48.7 
Obesity, %  13.2 15.8 16.9 17.9 
Lipid-lowering treatment prior to admission, %  24.5 25.5 22.7 24.7 
Aspirin, %  33.5 34.8 29.5 30.7 
Beta-blockers, %  17.8 18.3 15.1 16.0 
ACE inhibitors, %  21.6 21.6 19.2 19.5 
     
 
*SD indicates standard deviation; AHT, arterial hypertension; ACE inhibitors, angiotensin-conversion enzyme inhibitors. 
Quality Indicators at Admission 
The measurement of lipids at admission, independently of when this was done, reached 87.6% in the 
preintervention survey and increased slightly to 92.1% in the final survey. When analyzing the percentage 
of samples taken within the first 24 h, an increase was found ranging from 42.6% in the preintervention 
survey up to 56.5%, 56.6%, and 53.7% in the 3 later surveys, respectively (Table 4). 
The criterion for weight and height was not fulfilled in 66.5% of cases in the baseline survey, 
decreasing to 46.7% in the final survey (Table 4). 
Regarding the criteria for stratifying risk in the patients analyzed, an absolute improvement of 3.3% 
was found in the indicator for evaluation of ejection fraction (EF) when only ideal patients were 
considered (those in whom this should be carried out according to the agreed minimums) (Table 4) and of 
5.7% in the group of patients as a whole (Figure 3). The measurement of residual ischemia did not 
comply with the agreed minimums in the baseline survey in 18.9% of the patients; this decreased to 
10.8% in the final survey (a relative improvement of 43% regarding this criterion). Of the total patients, 
residual ischemia was not measured in 11.8%, 10.2%, 7.5%, and 6.3% of patients in each survey, 
respectively (Figure 3). In both tests the variability of the indicator decreased linearly between the centers 
from the time of the preintervention survey (P <.05). At the same time, a clear growing linear trend was 
observed in the global indicator (P <.05). 
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P Linear 
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Hospital management      
Percentage of patients who:      
– Had total cholesterol measured within the 
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– Had ejection fraction evaluated (out of the 
total who should be measured according to 







96.4 (846/878) .063 
– Did not comply with the agreed minimums 




16 (110/689) 11.6 (79/683) 10.8 (68/628) .013 










Treatment at the time of discharge      
Percentage of patients with prescriptions 
according to the minimum agreement. for: 
     















90.4 (605/669) NSe 





















– Inappropriate nitratesc 12.1 (88/729) 8.4 (64/766) 7.2 (55/761) 8.1 (59/730) NSe 
– Inappropriate calcium antagonists 
antagonistsc 
4.4 (42/949) 3.9 (36/922) 2.9 (27/947) 2.5 (24/950) .007 
Discharge report      
Percentage of patients whose discharge report 
contained specific recommendations on: 
     







72.2 (540/748) <.0001 
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– Information related to the administration 










– Target levels of lipid-lowering therapy and 
dosage 






– Target dose of ACE inhibitors (when 
indicated)  
9.3 (79/847) 15 (121/806) 
18.3 
(144/787) 
27.1 (212/782) <.0001 










      
 
*NS indicates non-significant; ACE inhibitors, angiotensin-conversion enzyme inhibitors. 
a Values expressed in percentage. When the criterion does not refer to the total number of patients, the number of patients who did or 
did not fulfill the criterion compared to the total to whom it applies is indicated in parentheses. 
b Percentage of patients who have each of the measures applied out of the total to whom it should be applied (ideal patients). 
c Yes, non-adherence to minimum agreements (not + yes, non-adherence to minimum agreements). Percentage of those to whom it 
was given when it should not have been given. 
d P of the test of comparison of percentages. The linear trend test was not applied. 
e There are no significant differences between the percentages of the 4 surveys at a 95% Confidence Interval, so the linear trend test 





Fig. 4 Pharmacological treatment at the time of discharge.  
Quality Indicators for Pharmacological Prescription 
The administration of acetylsalicylic acid (ASA) in the group of patients varied slightly between the 
different surveys (89.2%, 87.0%, 89.9%, and 91.7% in the baseline, second, third, and fourth surveys, 
respectively). Appropriate use of platelet aggregation inhibitors at the time of discharge varied slightly, 
although statistically significantly, from the baseline survey where a very high level of adherence (95.9%) 
(Table 4) was already observed. The use of nitrates was not justified in the baseline survey in 12.1% of 
cases, a quality indicator that improved gradually to 8.1% in the final survey, but without a clear linear 
trend (Table 4). A linear trend toward improvement was in fact found in the case of calcium antagonists.  
Figure 4 shows the percentage of patients who were prescribed angiotensin-conversion enzyme 
inhibitors (ACE inhibitors), beta-blockers (BB) and statins, as well as the percentage of those who were 
not prescribed any of these for no apparent reason. This information is complemented in Table 4 by the 
estimation of the percentage of patients who received such prescriptions versus those who should have 
(ideal patients). 
In the baseline survey, 68.6% of the patients who should have received statins as agreed did in fact 
receive them. This percentage improved in successive surveys up to 81.4% in the final survey, with an 
12.8% absolute improvement in the indicator and 19% in relative terms. 
Regarding prescriptions for BB, their use improved compared to the initial measurement, with a slight 
up-turn in their justified non-prescription in the final survey (8.7%, 7.9%, 4.1% and 5.6%, respectively) 
(decreasing linear trend, P <.05). 
Prescriptions for ACE inhibitors presented a similar pattern, with progressive improvements in the 
second and third surveys (5.9% and 4.5%, respectively) with regard to baseline (6.8%) and another 
increase in their underprescription in the fourth (6.3%) (Table 4 and Figure 4). 
Quality Indicators Referring  to the Recommendations Included in the Discharge Report 
The distribution of participants is presented in Figure 5 regarding the different recommendations 
agreed upon in the discharge report. This information is complemented in Table 4 by using the ideal 
patients as common denominators in each case. Anti-smoking advice was not given in 39.9% of patients 
who smoked in the baseline survey, although this indicator improved in the following surveys (30.5%, 
30.6%, and 27.8%, respectively). Advice concerning diet was not given when indicated to 15.9%, 17.2%, 




Fig. 5.Treatment at the time of discharge 
  
No recommendations regarding exercise were given in 41% of the cases in the preintervention and 
second surveys, although this indicator improved in the final survey compared to the previous two (35% 
and 32.6%, respectively) (statistically significant linear trend, P =.003). 
The target levels and doses of lipid-lowering drugs and the target doses of ACE inhibitors and BB in 
patients for whom they were indicated greatly improved in each survey.  
Discussion 
The CAM survey data demonstrate that it is possible to improve the quality of care in patients 
hospitalized for acute coronary syndromes in a multicenter context, with significant improvements in the 
procedures carried out, the pharmacological therapeutic measures, and the recommendations at the time 
of discharge. This improvement was obtained after the application of an educational intervention together 
with the measurement of and feedback on the data evaluated in each center. 
Multiple registries are available on the management and treatment of patients with acute coronary 
syndromes.3-11 The methodology used and the value of the information obtained have been subject to 
criticism.21 However, this current project differs from a conventional registry in several respects. First, it 
provides estimations of the percentage of patients who receive a given treatment (or other measures) out 
of those who should receive it, and not just out of the total number of patients as found, with few 
exceptions, in the available registries. This was done with the prior explicit written agreement of all the 
centers involved in regard to the interventions that should be carried out. Second, an intervention common 
to all the participating hospitals was done with a later reassessment to evaluate its potential benefits; this 
is not the aim of a registry and thus is not available in any Spanish registry. There are similar studies on 
different intervention techniques in the international or Spanish context, but none of these are multicenter 
studies.22-24  Such intervention strategies aimed at improving quality have shown their efficacy in patients 
with AMI, both locally and at a multicenter level. The interest raised by quality issues in cardiology has 
led the American College of Cardiology and the American Heart Association to develop quality 
improvement programs for AMI with more complex tools that have demonstrated their applicability and 
efficacy, such as the Guidelines Applied in Practice and Get With the Guidelines projects, 
respectively.25,26  These strategies have also demonstrated their efficacy in other areas in patients with 
ischemic heart disease, such as lipid management or coronary surgery.27,28  In Spain, the results of the 
PRESENTE survey, an intervention program for postinfarction patients and their families, have recently 
been published showing significant improvements in secondary prevention measures. This survey dealt 
with a different population and intervention, but whose initial aim was to improve quality of care via 
intervention programs.29 
Analysis of Improvement 
All the quality indicators related to hospital management (analysis of cholesterol, weight and height, 
and measurement of EF and ischemia) improved after the intervention, with gradual positive increases in 
the three postintervention surveys. The most striking improvements occurred in the measurement of the 
lipid profile within the first 24 h (an absolute increase of 9.8 points) and in the measurement of weight 
and height at admission (an absolute increase of 22 points). Obviously, these match those areas with a 
greater chance of improvement at baseline. However, absolute improvements of 5.5% should not be 
ignored in the correct assessment of ischemia before discharge or of 5.7% in the evaluation of ventricular 
function.  
Regarding pharmacological prescription at the time of discharge, if the indications for a drug are 
analyzed without assessing whether it was prescribed for an “ideal” patient, the figures are similar to the 
prescription for ASA (89.2%-91.7% in the CAM study vs 87.8% in the PREVESE II12  study or 93% in 
the PEPA5  study). The figures diverge regarding the use of ACE inhibitors, BB and statins, these being 
greater in our survey (56.6% ACE inhibitors, 69.3% BB, and 63.6% statins at baseline vs the PREVESE 
II data, with 46.4% ACE inhibitors, 45.1% BB, and 29.4% statins, or vs the PEPA data, with 20% ACE 
inhibitors, 42% BB, and 6% statins). First, these differences can be accounted for by the fact that in the 
CAM survey acute coronary syndromes with and without ST segment elevation were analyzed jointly; 
second, by the amount of time that had elapsed since those registries were created since awareness about 
and evidence of the use of secondary prevention measures is currently greater.  
When the “ideal” patients are actually analyzed (those who did not have any absolute or relative 
contraindications for the indicator under analysis), our results can only be compared with those of the 
Guidelines Applied in Practice project.25  This survey was carried out in patients with AMI in which a 
different intervention tool was used. A change was found from 89% preintervention to 93% 
postintervention in prescriptions for BB, from 80% to 86% for ACE inhibitors, and from 68% to 75% for 
statins. In our survey there was a change (when comparing the baseline to the fourth survey figures) in 
prescriptions for BB in ideal patients from 88.9% to 92.9% (fourth survey); from 89.3% to 90.4% for 
ACE inhibitors; and from 68.6% to 81.4% for statins (Table 4). These data are similar, except in the ACE 
inhibitors group, probably because the indication level was set higher in our case and thus there was a 
smaller chance for improvement.  
There was an improvement after the intervention regarding the recommendations at the time of 
discharge on smoking, diet, exercise, or target dose of drugs (ACE inhibitors or BB), although this was 
variable (from 1.5 improvement points in stating appropriate recommendations for diet, with 
nonsignificant differences, up to 21.6 improvement points regarding stating the target levels of low-
density lipoprotein cholesterol (LDL-C) in the discharge report). It should be pointed out that, regarding 
basic aspects such as diet or exercise unrelated to pharmacological treatment, smaller improvements were 
obtained. One possible way to read this is that the interventions used in this survey which lead to changes 
in lifestyle are not as effective as the pharmacological ones. It may be necessary to carry out structural 
and multidisciplinary changes in patient care and, in the longer term, with the more active involvement of 
other professionals (nurses and others).  
Most of the observed improvements were accompanied by or were due to a reduction in variability 
between centers, which constitutes, in our opinion, the added value of the multicenter approach. 
Limitations 
This study has several limitations. First, at the time of publication, we lacked a control group of 
hospitals with which to compare the efficacy of the intervention. Due to this, it cannot be completely 
ruled out that some of the observed improvements may have also occurred in the absence of any 
intervention. Nevertheless, this seems unlikely, especially regarding the measures that have been 
established for a long time (e.g., the measurement of cholesterol within the first 24 h, prescriptions for BB 
at discharge, etc). Second, the participating centers were not selected randomly. The process of 
assignment to the survey was voluntary and, therefore, this could already imply concern for improvement 
in these centers. This might partly explain the good baseline situation. However, this could not be the case 
in centers without a suitable level of motivation. In brief, and if this is correct, improvement will occur 
only if there is a desire to improve, which seems reasonable. In addition, there was no external control to 
guarantee the objectivity of data collection. The probability of the deliberate alteration of data collection 
seems low since, given the design of the survey, confidentiality was maintained regarding the results of 
each center. Thus, modifying the data would give any such center a distorted picture of its own situation, 
without being counterbalanced by the recognition of a job well done. The most likely situation is that, as 
it was known that the intervention was being monitored, certain practices would be partially changed. 
However, this is not regarded as a problem, but as a desirable outcome in the context of a program 
designed to continually improve quality.  
Attention should be drawn to the apparent decrease in some of the quality indicators in the final 
survey compared to the two previous surveys, which raises the question of whether this can be attributed 
to a loss of motivation once the first phases had ended. If so, more reliable tools or structural strategies 
need to be constructed to avoid this situation.  
This project is innovative in that it is the first to approach improvement in quality for patients with 
ischemic heart disease in a multicenter context. Whether this intervention can be improved or not, or 
whether it persists or not, is debatable. However, it does provide clear benefits regarding the proposed 
quality indicators based on this new methodology, although this is still being developed. On the other 
hand, this survey is also novel because it provides estimations regarding the patients who should receive 
each treatment or intervention. In our opinion, this provides a more realistic vision of the magnitude of 
the gap between what is done and what should be done, as well as a better idea of how much 
improvement is possible.  
In conclusion, our survey shows that the application of an intervention based on quality indicators can 
improve the quality of care in patients with ischemic heart disease in a multicenter context.  
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